OOIR: Observatory of International Research

Papers

(The TQCC of Journal of the Peripheral Nervous System is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision	187
Guillain‐Barré syndrome during SARS‐CoV‐2 pandemic: A case report and review of recent literature	149
COVID‐19 and the peripheral nervous system. A 2‐year review from the pandemic to the vaccine era	46
Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis	44
Evolving concepts on the role of dyslipidemia, bioenergetics, and inflammation in the pathogenesis and treatment of diabetic peripheral neuropathy	40
The neuropathy in hereditary transthyretin amyloidosis: A narrative review	33
Platinum accumulation in oxaliplatin‐induced peripheral neuropathy	28
Oxaliplatin‐ and docetaxel‐induced polyneuropathy: clinical and neurophysiological characteristics	26
Peripheral neuropathy symptoms in wild type transthyretin amyloidosis	22
Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes	22
Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel‐induced peripheral neurotoxicity in breast cancer patients	21
Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features	18
Guillain‐Barré syndrome decreases in Singapore during the COVID‐19 pandemic	18
A longitudinal and cross‐sectional study of plasma neurofilament light chain concentration in Charcot‐Marie‐Tooth disease	17
Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: Data from the Italian CIDP database	15
Loss of function MPZ mutation causes milder CMT1B neuropathy	15
Acute and chronic inflammatory neuropathies and COVID‐19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP)	15
Enhancing peripheral nerve regeneration with neurotrophic factors and bioengineered scaffolds: A basic science and clinical perspective	14
Motor chronic inflammatory demyelinating polyneuropathy (CIDP) in 17 patients: Clinical characteristics, electrophysiological study, and response to treatment	14
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review	14
Antecedent infections in Guillain‐Barré syndrome in endemic areas of arbovirus transmission: A multinational case‐control study	13
Diabetic polyneuropathy: Bridging the translational gap	13
An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM	12
Acquired and inherited amyloidosis: Knowledge driving patients' care	12
Report of a fulminant anti‐pan‐neurofascin‐associated neuropathy responsive to rituximab and bortezomib	12

Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy	12
The diagnostic accuracy of the small fiber neuropathy symptoms inventory questionnaire (SFN‐SIQ) for identifying pure small fiber neuropathy	12
Antecedent infections inGuillain‐Barrésyndrome patients from south India	12
Cutaneous and muscular afferents from the foot and sensory fusion processing: Physiology and pathology in neuropathies	11
The Hippo pathway: Horizons for innovative treatments of peripheral nerve diseases	11
Serum neurofilament light chain as a reliable biomarker of hereditary transthyretin‐related amyloidosis—A Swiss reference center experience	10
Incidence and mortality rates of Guillain‐Barré syndrome in Serbia	10
Recent advances in the treatment of Charcot‐Marie‐Tooth neuropathies	10
Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges	10
Acute nitrous oxide‐induced neuropathy mimicking Guillain‐Barré syndrome	9
Associations of Guillain‐Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database	9
Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination: A report of three cases and review of the literature	9
Diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy in clinical practice: A survey among Dutch neurologists	9
Ataxia pancytopenia syndrome due to SAMD9L mutation presenting as demyelinating neuropathy	9
Sensory neuronopathies: A case series and literature review	8
A prospective study on surgical management of foot deformities in Charcot Marie tooth disease	8
Impact of drug formulations on kinetics and toxicity in a preclinical model of paclitaxel‐induced neuropathy	8
Charcot–Marie–Toothneuropathies: Current gene therapy advances and the route toward translation	8
The Brighton Collaboration case definition: Comparison in a retrospective and prospective cohort of children with Guillain‐Barré syndrome	8
Reliability of the Charcot‐Marie‐Tooth functional outcome measure	8
Variants of aminoacyl‐tRNA synthetase genes in Charcot‐Marie‐Tooth disease: A Korean cohort study	7
From pathogenesis to personalized treatments of neuropathies in hematological malignancies	7
Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands	7
Charcot‐Marie‐Tooth disease: Genetic profile of patients from a large Brazilian neuromuscular reference center	7
Genetic spectrum of MCM3AP and its relationship with phenotype of Charcot‐Marie‐Tooth disease	7
ABSTRACT	7
Proximal weakness involvement in the first Italian case of Charcot‐Marie‐Tooth 2CC harboring a novel frameshift variant in NEFH	6
Variations within Toll‐like receptor (TLR) and TLR signaling pathway‐related genes and their synergistic effects on the risk of Guillain‐Barré syndrome	6
Focal chronic inflammatory demyelinating polyradiculoneuropathy: Onset, course, and distinct features	6
Early onset demyelinating Charcot‐Marie‐Tooth disease caused by a novel in‐frame isoleucine deletion in peripheral myelin protein 2	6
Severe distinct dysautonomia in RFC1‐related disease associated with Parkinsonism	6
Frequency dependent, reversible focused ultrasound suppression of evoked potentials in the reflex arc in an anesthetized animal	6
Feasibility of assessing progression of transthyretin amyloid polyneuropathy using nerve conduction studies: Findings from the Transthyretin Amyloidosis Outcomes Survey (THAOS)	5
The epidemiology of Guillain‐Barré syndrome in Thailand over 13 years (2005‐2017): A nationwide population‐based retrospective cohort study	5
Diagnosis of Guillain‐Barré syndrome and validation of the Brighton criteria in Malaysia	5
Description of a patient cohort with Hereditary Sensory Neuropathy type 1 without retinal disease Macular Telangiectasia type 2 ‐ implications for retinal screening in HSN1	5
Autoimmune nodo‐paranodopathies 10 years later: Clinical features, pathophysiology and treatment	5
Validation of the Italian version of the Charcot‐Marie‐Tooth disease Pediatric Scale	5
Comorbidities, anthropometric, demographic, and lifestyle risk factors for ulnar neuropathy at the elbow: A case control study	5
Neutrophil‐lymphocyte ratio in Guillain‐Barré syndrome: A prognostic biomarker of severe disease and mechanical ventilation in Bangladesh	5
Comparing neuropathy in multiple myeloma and AL amyloidosis	5
Riveting hammer vibration damages mechanosensory nerve endings	5
Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research	5
Vitamin B6 levels do not correlate with severity of neuropathy in chronic idiopathic axonal polyneuropathy	5
A new de novo SYT2 mutation presenting as distal weakness. Neuropathy or neuromuscular junction dysfunction?	5
Vibratory testing with the 64 Hz Rydel‐Seiffer tuning fork and its relation to the sural nerve action potential	5
Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin‐induced peripheral neurotoxicity	5
Expanding the spectrum of SPTLC1‐related disorders beyond hereditary sensory and autonomic neuropathies: A novel case of the distinct “S331 syndrome”	5
Long read sequencing overcomes challenges in the diagnosis of SORD neuropathy	5
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome	5